SGMT
Sagimet Biosciences Inc. Series A
9.10$
-12.6%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| – | – | – | – | – | -100.0% | – | |
| – | +40.9% | +8.1% | -3.0% | – | – | – | |
| – | – | – | – | – | – | – | |
| – | -2.5% | +136.4% | +28.8% | -20.6% | +94.4% | +1.6% | |
| – | -45.1% | +36.1% | +40.1% | +111.3% | +23.5% | +11.4% | |
| – | -19.0% | +108.1% | +30.9% | +5.4% | +66.3% | +4.5% | |
| – | – | – | – | – | – | – | |
| – | -100.0% | – | – | – | – | – | |
| – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.